Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9200651-thea-pharma-inc-launches-iyuzeh/ "The U.S. launch of ...
(RTTNews) - Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent ...
IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ...
CHICAGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- TearClear, an ophthalmic pharmaceutical company that transforms trusted drugs into branded best-in-class therapies, announced today that the company’s lead ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. TearClear has initiated a phase 3 trial evaluating ...
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- TearClear, a late clinical stage ophthalmic pharmaceutical company, has filed an Investigational New Drug (IND) application to conduct a registrational study ...
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of latanoprost ophthalmic solution, 0.005% (0.05 mg/mL). Glenmark’s latanoprost ophthalmic solution, 0.005% (0.05 mg/mL) is ...
Rhopressa TM (netarsudil ophthalmic solution) 0.02%, is a novel eye drop that we believe, if approved, would become the only once-daily product available that, based on Aerie’s preclinical studies, ...
The Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is the fourth ophthalmic product launched by Glenmark. Marc Kikuchi, President & Business Head, North America at Glenmark, expressed enthusiasm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback